Endocrinology

Supportive Care

Questions discussed in this category

Would you favor oral bisphosphonates over intravenous formulations for patients with hormone sensitive prostate cancer and androgen deprivation therapy (ADT) related osteopenia?

1 Answer available

Should GLP-1 agonists be held during chemotherapy?

3 Answers available

In SIADH due to malignancy, do you prefer to use free water restriction or salt tablets?

Or other therapy - e.g., tolvaptan? Free water restriction may hinder QOL. Salt tablets may raise levels more quickly but have risks of edema and hype...

1 Answer available

Are there any concerns regarding side effects in changing from denosumab to zolendronic acid or vice versa?

1 Answer available

For patients on a bone-modifying agent for osteoporosis/severe osteopenia in the context of adjuvant AI therapy, how do you manage the bone-modifying agent once their AI course is complete?

1 Answer available

For patients with cancer receiving a bone-modifying agent (bisphosphonate or denosumab) who suffer a fracture requiring stabilization or reconstruction, how do you manage the bone-modifying agent peri-operatively?

Is there concern for impaired healing? Do you pause therapy and for how long?

1 Answer available

Papers discussed in this category

J Clin Oncol, 2019 Sep 18

Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline.

Cancer Chemother Pharmacol, 2021 Mar 31

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.

J Bone Miner Metab, 2020 Jul 12

Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.

BMJ open, 2024 Oct 09

Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study.

JAMA network open, 2024 Jul 01

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2024 Sep 26

Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024.

Endocrinology

Supportive Care

Questions discussed in this category

Papers discussed in this category

Related Topics in Endocrinology